Marc-Thorsten Hütt, Keedrian I. Olmstead, Pierre-Olivier Vidalain, Rautureau Gjp, Rodrigue Rossignol, Fabian V. Filipp, Piotr Nyczka, Olivier Diaz, Lotteau, Baptiste Panthu, Laure Perrin-Cocon, Anne Aublin-Gex, Clémence Jacquemin, Patrice Andre, Nivea Dias Amoedo, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Helmholtz Zentrum München Institute of Computational Biology Neuherberg, Germany, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de RMN à très hauts champs de Lyon (CRMN), École normale supérieure - Lyon (ENS Lyon)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Jacobs University [Bremen], Cellomet [CHU Pellegrin, Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) (U1211 INSERM/MRGM), Université de Bordeaux (UB)-Groupe hospitalier Pellegrin-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)
Hexokinases catalyze the first step of glycolysis by phosphorylating glucose. In the liver, normal hepatocytes express the low-affinity hexokinase 4, also known as glucokinase (GCK), which is adapting hepatocyte function to glycaemia. Conversely, hepatocellular carcinoma (HCC) cells express the high-affinity hexokinase 2 (HK2) to sustain tumor proliferation even at low glucose concentrations. A switch from GCK to HK2 isoenzymes is occurring during the transition from primary hepatocytes to HCC. HK2 induction is a recurrent event in the carcinogenic process and relates to the highly glycolytic phenotype of HCC but the consequence of GCK loss is unknown. To explore functional consequences of the GCK-to-HK2 isoenzyme switch, HK2 was knocked-out in the HCC cell line Huh7 and replaced by GCK, to generate the Huh7-GCK+/HK2- cell line. We then compared the transcriptomic, metabolomic and immunological profiles of both cell lines. The analysis of transcriptomic data from human HCC tumors shows that GCK and HK2 expression levels are inversely correlated and associated with patient survival. The replacement of HK2 by GCK rewired central carbon metabolism and restored some essential metabolic functions of normal hepatocytes such as lipogenesis, VLDL secretion and glycogen storage. It also reactivated innate immune responses and sensitivity to NK lysis. Our results suggest that the GCK-to-HK2 isoenzyme switch is playing a key role in dedifferentiation and immune escape of HCC cells.